We are live on ! Find out more
AMLX icon

Amylyx Pharmaceuticals
AMLX

72 hedge funds and large institutions have $300M invested in Amylyx Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 72 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

980% more call options, than puts

Call options by funds: $5.76M | Put options by funds: $533K

41.48% more ownership

Funds ownership: 0% → 41.48% (+41%)

Holders
72
Holders Change
+72
Holders Change %
–
% of All Funds
1.14%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
72
Increased
–
Reduced
–
Closed
–
Calls
$5.76M
Puts
$533K
Net Calls
+$5.22M
Net Calls Change
+$5.22M

Top Buyers

Rank Fund Capital Flow
1
Viking Global Investors
Viking Global Investors
Connecticut
+$162M
2
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
+$62.2M
3
BC
Boxer Capital
California
+$49.7M
4
PA
Perceptive Advisors
New York
+$33.3M
5
RSCM
Rock Springs Capital Management
Maryland
+$22.5M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$1.06M +$1.86M +82,170 New
AG
27
Artal Group
Luxembourg
$964K +$1.69M +75,000 New
Charles Schwab
28
Charles Schwab
California
$939K +$1.65M +73,027 New
Balyasny Asset Management
29
Balyasny Asset Management
Illinois
$808K +$1.42M +62,915 New
OMC
30
Oasis Management Company
Cayman Islands
$643K +$1.13M +50,000 New
BFM
31
Boothbay Fund Management
New York
$620K +$1.09M +48,271 New
Susquehanna International Group
32
Susquehanna International Group
Pennsylvania
$598K +$1.05M +46,565 New
Morgan Stanley
33
Morgan Stanley
New York
$544K +$956K +42,345 New
PI
34
PFS Investments
Georgia
$508K +$893K +39,558 New
Adage Capital Partners
35
Adage Capital Partners
Massachusetts
$478K +$840K +37,200 New
CM
36
Caption Management
Oklahoma
$472K +$828K +36,667 New
AI
37
Atom Investors
Texas
$471K +$829K +36,691 New
CSS
38
Cubist Systematic Strategies
Connecticut
$449K +$789K +34,914 New
Jane Street
39
Jane Street
New York
$376K +$661K +29,246 New
Walleye Capital
40
Walleye Capital
New York
$362K +$637K +28,187 New
Bank of New York Mellon
41
Bank of New York Mellon
New York
$340K +$597K +26,451 New
CCM
42
CAAS Capital Management
New York
$218K +$384K +17,000 New
Squarepoint
43
Squarepoint
New York
$193K +$339K +15,000 New
N
44
Nuveen
North Carolina
$170K +$299K +13,230 New
PVI
45
Pura Vida Investments
New York
$129K +$226K +10,000 New
MIM
46
MetLife Investment Management
New Jersey
$87.2K +$153K +6,785 New
Deutsche Bank
47
Deutsche Bank
Germany
$69K +$121K +5,349 New
Simplex Trading
48
Simplex Trading
Illinois
$66K +$117K +5,198 New
AIG
49
American International Group
New York
$61K +$108K +4,760 New
JP Morgan Chase
50
JP Morgan Chase
New York
$58K +$102K +4,497 New
1
2
3

AMLX Hedge Fund Activity: Q1 2022 in Review

72 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q1 2022, worth a combined $300M.

Buyers outnumbered sellers: 72 funds opened new AMLX positions and 0 closed out — a net gain of 72 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Viking Global Investors, opening a new position worth an estimated $162M.

  • 72 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q1 2022, up from 0 in Q4 2021.
  • Funds reported $300M of Amylyx Pharmaceuticals stock for Q1 2022.
  • 72 funds opened new Amylyx Pharmaceuticals positions in Q1 2022 and 0 closed out, a net change of +72 holders.
  • The largest Amylyx Pharmaceuticals buyer in Q1 2022 was Viking Global Investors, an estimated $162M added.

Based on aggregated 13F filings for Q1 2022.